NDA 021897 · Alkermes
Vivitrol
Naltrexone · Intramuscular
Priority reviewLast checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Apr 13, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
478
101 Phase 3, 23 recruiting
FAERS reports
31,043
8,878 serious, 1,344 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 31, 2026.
Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support. VIVITROL contains naltrexone, an opioid antagonist, and is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. Patients should not be actively drinking at the time of initial VIVITROL administration ( 1.1 ). VIVITROL is indicated for the prevention of relapse to opioid dependence, following opioid detoxification ( 1.2 ). VIVITROL should be part of a comprehensive management program that includes psychosocial support ( 1 ). 1.1 Alcohol Dependence VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. Patients should not be actively drinking at the time of initial VIVITROL administration. 1.2 Opioid Dependence VIVITROL is indicated for the prevention of relapse to opioid dependence, following opioid detoxification.
Mechanism: Naltrexone is an opioid antagonist with highest affinity for the mu opioid receptor. Naltrexone has little or no opioid agonist activity.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 12, 2010 Supplement 15 · Efficacy · priority review LabelLetter
- Apr 13, 2006 Original approval · Type 3 - New Dosage Form · priority review LabelOther Important Information from FDALetter
1 products under this application
- VIVITROL · NALTREXONE 380MG/VIAL · FOR SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Naltrexone" as an intervention, any sponsor and status, largest first.
- Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)Pivotal-lookingTerminated
Orexigen Therapeutics, IncIndustry
NCT01601704 · 8,910 participants · Start Jun 2012 · Primary completion Aug 2015
Drug: NB32; PBO · For: Obesity; Overweight
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 224 sites in all
- Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)Pivotal-lookingActive, not recruiting
Currax PharmaceuticalsIndustry
NCT06098079 · 8,600 participants (planned) · Start Jan 3, 2024 · Primary completion Jan 2029
Drug: Naltrexone-Bupropion (NB) Combination; Placebo · For: Obesity
Sites: Birmingham, Alabama; Cullman, Alabama; Mobile, Alabama · 140 sites in all
- A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese SubjectsPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00532779 · 1,742 participants · Start Oct 2007 · Primary completion May 2009
Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day; Naltrexone SR 32 mg/Bupropion SR 360 mg /day and 1 more · For: Obesity; Overweight
Sites: Birmingham, Alabama; Fairhope, Alabama; Chandler, Arizona · 34 sites in all
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)Pivotal-lookingActive, not recruiting
NYU Langone HealthAcademic, hospital or other
NCT04464980 · 1,516 participants · Start Jun 8, 2021 · Primary completion Dec 31, 2026
Drug: SL-BUP; XR-BUP and 1 more · For: Opioid Use Disorder (OUD)
Sites: Little Rock, Arkansas; Tarzana, California; Bridgeport, Connecticut · 21 sites in all
- A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese SubjectsPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00567255 · 1,496 participants · Start Dec 2007 · Primary completion Jun 2009
Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day; Placebo · For: Obesity; Overweight
Sites: Phoenix, Arizona; Hot Springs, Arkansas; Carmichael, California · 36 sites in all
- COMBINE (Acamprosate/Naltrexone)Pivotal-lookingCompleted
University of North Carolina, Chapel HillAcademic, hospital or other
NCT00006206 · 1,375 participants · Start Aug 1997
Drug: naltrexone (Revia); acamprosate (Campral) · For: Alcoholism
Sites: New Haven, Connecticut; Miami, Florida; Belmont, Massachusetts · 12 sites in all
- The Study of Brave-LC LDN Treatment TrialPivotal-lookingNot yet recruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07916259 · 1,300 participants (planned) · Start Nov 16, 2026 · Primary completion Dec 31, 2028
Drug: naltrexone · For: Post-acute COVID-19 Syndrome
Sites: Birmingham, Alabama; Chula Vista, California; Denver, Colorado · 13 sites in all
- A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification ProgramPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00456521 · 793 participants · Start Mar 2007 · Primary completion Dec 2008
Drug: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day; Placebo · For: Obesity; Overweight
Sites: La Jolla, California; Denver, Colorado; Gainesville, Florida · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site reaction4,410
- injection site pain3,180
- nausea2,165
- alcoholism1,959
- injection site mass1,927
- fatigue1,824
- pain1,671
- drug ineffective1,580
- off label use1,525
- headache1,516
- feeling abnormal1,412
- drug dependence1,378
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 36 |
| 2006 | 23 |
| 2007 | 52 |
| 2008 | 62 |
| 2009 | 38 |
| 2010 | 51 |
| 2011 | 55 |
| 2012 | 123 |
| 2013 | 151 |
| 2014 | 281 |
| 2015 | 1,180 |
| 2016 | 1,861 |
| 2017 | 2,273 |
| 2018 | 6,405 |
| 2019 | 3,346 |
| 2020 | 3,695 |
| 2021 | 2,783 |
| 2022 | 2,581 |
| 2023 | 1,962 |
| 2024 | 1,465 |
| 2025 | 1,428 |
| 2026 | 1,185 |
Recalls
4 FDA enforcement reports for this application.
Sep 26, 2019 · Class II · Terminated
Labeling: Not Elsewhere Classified. Drug product kit recalled due to 1 inch needles being placed in the 1 1/2 inch needle cardboard sleeve labelled as administration needles. The product vial is not impacted.
Aug 8, 2019 · Class II · Terminated
Labeling: Not Elsewhere Classified. Drug product kit recalled due to 1 inch needles being placed in the 1 1/2 inch needle cardboard sleeve labelled as administration needles. The product vial is not impacted.
Mar 4, 2014 · Class II · Terminated
Customer complaints for failure to deliver the dose.
Nov 6, 2012 · Class II · Terminated
Lack of Assurance of Sterility: Product did not meet the criteria for container closure integrity testing during routine 24 month stability testing.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vivitrol (Naltrexone Microspheres)
2024 spending
$73.1M
Beneficiaries
9,867
44,521 claims
Per beneficiary
$7,408
$1,621.97 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $36,655,227 |
| 2021 | $43,303,110 |
| 2022 | $50,748,174 |
| 2023 | $62,245,696 |
| 2024 | $73,090,051 |
Part B: Vivitrol (Naltrexone Microspheres) · HCPCS J2315
2024 spending
$2.6M
Beneficiaries
601
2,228 claims
Per beneficiary
$4,344
2024 ASP limit $4.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,711,448 |
| 2021 | $2,075,658 |
| 2022 | $2,478,785 |
| 2023 | $2,324,438 |
| 2024 | $2,611,004 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
McPheeters M, O'Connor EA, Riley S, et al. · JAMA 2023 · Comparative Study, Meta-Analysis
- Bupropion and Naltrexone in Methamphetamine Use Disorder.
Trivedi MH, Walker R, Ling W, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
- Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF, O'Malley SS, Ciraulo DA, et al. · JAMA 2006 · Multicenter Study, Randomized Controlled Trial
- Pharmacological management of gambling disorder: A systematic review and network meta-analysis.
Ioannidis K, Del Giovane C, Tzagarakis C, et al. · Compr Psychiatry 2025 · Systematic Review, Network Meta-Analysis
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R, Murad MH, Chandar AK, et al. · JAMA 2016 · Research Support, N.I.H., Extramural, Systematic Review
- Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
Grilo CM, Lydecker JA, Fineberg SK, et al. · Am J Psychiatry 2022 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Alkermes
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.